Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist

Journal of Medicinal Chemistry

Volumn 44, Issue 21, 2001, Pages 3343-3346

  Tagat, J R ^a   Steensma, R W ^a   McCombie, S W ^a   Nazareno, D V ^a   Lin, S I ^a   Neustadt, B R ^a   Cox, K ^a   Xu, S ^a   Wojcik, L ^a   Murray, M G ^a   Vantuno, N ^a   Baroudy, B M ^a   Strizki, J M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 [3 METHYL 4 [1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL] 1 PIPERAZINYL] PIPERIDINE N1 OXIDE; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MUSCARINIC RECEPTOR; PIPERAZINE DERIVATIVE; SCH 350634; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CYTOKINE PRODUCTION; DOG; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MONKEY; NONHUMAN; PERIPHERAL CIRCULATION; RAT; RECEPTOR BLOCKING; VIRUS INHIBITION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; CYCLIC N-OXIDES; DOGS; HIV-1; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; PIPERAZINES; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035846070     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0155401     Document Type: Article

References (21)

1. Report on the Global HIV/AIDS Epidemic
2. Primary HIV-1 resistance
3. Chemokine receptors as HIV co-receptors: Targets for therapeutic intervention in AIDS
4. HIV-1 entry: An expanding portal for drug discovery
5. Privileged structures: An update
6. Viral exploitation and subversion of the immune system through chemokine mimicry
7. Discovery of novel, potent, and selective small molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quarternary ammonium moiety
8. 1,3,4-Trisubstituted pyrrolidine CCR5 Antagonists. Part 1: Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements
9. Discovery of potent, orally bioavailable CCR5 antagonists-1
10. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)methyl piperazine as a key pharmacophore element
11. Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor
12. A novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rat
13. Highly enantioselective borane reductions of ketones catalyzed by chiral oxaborolidines
14. An asymmetric synthesis of MK-0417. Observations on oxaborolidine-catalyzed reductions
15. Enantioselective total synthesis of indolizidine alkaloids 167B and 209D
16. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures